Antibody characterization data generated by Twist supports TuneLab AI models designed to accelerate antibody discovery Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, announced an agreement with Lilly TuneLab. The collaboration supports Antibody Drug Discovery through AI and machine learning technologies. Lilly TuneLab is a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist Bioscience will provide antibody characterization data services for TuneLab.
The services will also support AbLab, an antibody developability prediction model. Through this arrangement, Twist will help generate high-quality experimental data for TuneLab users. TuneLab aims to accelerate biotech innovation through AI/ML drug discovery models. These models use decades of Lilly’s proprietary research data for training. Participating companies can use the models to evaluate candidate molecules more efficiently. As a result, researchers can potentially make faster decisions during antibody development. Under the agreement, TuneLab users can order antibody services from Twist. Users can also select preferred Twist protocols for generating wet lab data. This approach connects experimental research with AI-enabled drug discovery. Therefore, researchers can combine laboratory results with advanced prediction models during antibody discovery.
“The quality of an AI model’s output depends on the quality of the data used to train it,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Twist has the scale and high-throughput capabilities to generate consistent and reliable antibody characterization data these models need to be trained on. Lilly’s leadership in empowering AI-enabled drug discovery and its impressive network of partnerships create a powerful ecosystem that brings together advanced models and high-quality data. Through this arrangement, TuneLab users can select preferred protocols to generate high-quality data with preferred pricing – both helping them to more efficiently select antibody sequences against their targets and contribute that data back to TuneLab for federated training.”
Twist Bioscience Supports AI-Driven Antibody Discovery
Twist will provide antibody characterization services through the TuneLab ecosystem. These services will generate data that can support AI model training and development. The arrangement focuses on producing consistent and reliable antibody characterization data. This data can help improve the information available to AI/ML drug discovery models. Twist Bioscience brings high-throughput capabilities to the collaboration. The company can use its scale to generate antibody characterization data efficiently.
The collaboration combines Twist’s laboratory capabilities with Lilly’s AI/ML technology. In addition, TuneLab provides participating companies with access to models trained on Lilly research data. Researchers can use these capabilities to assess antibody sequences against specific targets. They can then contribute generated data back to TuneLab for federated training. This process creates a connection between laboratory experimentation and AI-driven discovery. Consequently, users can potentially improve how they identify and select antibody candidates.
Lilly TuneLab Expands Biotech Innovation Ecosystem
Lilly TuneLab is part of Lilly Catalyze360. It’s all part of a bigger effort that includes Lilly Ventures, Lilly Gateway Labs and Lilly ExploR&D. All of these programs offer resources to help support biotech innovation. These resources include strategic capital, laboratory space, technology and research & development capabilities. Lilly TuneLab is bringing artificial intelligence/machine learning drug discovery capabilities to this broader ecosystem. Participating companies will have access to prediction models developed from Lilly’s proprietary research data.
Twist Bioscience meanwhile is offering antibody characterization data services in support of the platform. This creates a link between high-quality wet lab data and AI-enabled research. The partnership also provides TuneLab users access to preferred Twist protocols. Thus, antibody data can be generated by users with standard laboratory workflows. Participating TuneLab users get preferred pricing with the deal. Researchers can also provide the generated data to TuneLab for federated training.
AI is increasingly being use in pharmaceutical research but there is a need for high quality data to develop models. In the discovery of antibody drugs, computational methods are increasingly being combined with laboratory experimentation. The deal connects the two spaces for Twist Bioscience and Lilly TuneLab. The partnership combines antibody characterization, AI/ML models, and wet lab work.
The collaboration is intended to make it easier to choose an antibody sequence more efficiently. It also offers a framework to connect experimental results to discovery models driven by Artificial Intelligence. The model could give biotech companies access to powerful tools for discovering drugs. At the same time, Twist provides the necessary laboratory capabilities to generate antibody characterization data.
The partnership deepens the bridge between AI and experimental research. It also advances the larger goal of accelerating antibody discovery through integrated technology and data. Lilly TuneLab will continue to be part of Lilly Catalyze360 with its other biotech innovation initiatives. Twist Bioscience will also offer its antibody characterization capabilities to the TuneLab platform.
The companies want to combine advanced AI models with reliable experimental data. This approach supports the ongoing efforts to advance antibody drug discovery and biotech innovation.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
